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Summary This study describes the ﬁrst case of extensively drug-resistant tuber-
culosis (XDR-TB) in the Thames Valley and South East Region and discuss the public
health implications, highlighting the need to integrate current epidemiological
knowledge with clinical expertise in order to diagnose drug-resistant tuberculosis
(TB) early.The management of the XDR-TB patients is challenging with few treatment
options, expensive therapy, side effects of drugs and a longer course of the treat-
ment.
© 2011 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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uberculosis (TB) causes 1.7 million deaths each
ear worldwide. Multi-drug resistant (MDR) and
xtensively drug-resistant tuberculosis (XDR-TB)
ave become urgent and worrisome threats to
lobal health. XDR-TB is resistant to both ﬁrst and
econd line anti-tuberculosis therapy. As a result, it
an be extremely difﬁcult to treat and is associated
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oi:10.1016/j.jiph.2011.06.003ith a higher mortality than non-resistant strains
1], especially in areas with a high prevalence of
IV.
In 2008, 963 XDR-TB cases were reported to
he WHO worldwide [2]. Between 1995 and 2008
en XDR-TB cases were reported in the UK, ﬁve
f whom died [3]. Of the countries where it has
een reported, XDR-TB is thought to represent, on
verage, 5.4% of all MDR-TB cases [2]. However,
n Eastern European countries, such as Estonia and
ithuania, this proportion is much higher (12.5% and
4.5% respectively) [2].
This case report describes public health issues
rising from a case of XDR-TB in the Thames
alley.
Sciences. Published by Elsevier Ltd. All rights reserved.
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Table 1 Timeline of events in the clinical history and
management of the case from presentation until XDR-
TB diagnosis and subsequent discharge.
Date Event
4th May 08 Presented to A&E
May, June, July 08 Saw GP several times over 3
month period with no
improvement in symptoms
21st August 08 X-ray showed small area of
consolidation
28th August 08 Acid fast bacilli on microscopy
29th August 08 TB treatment started with four
drug regimen (rifampicin,
isoniazid, ethambutol and
pyrazinamide)—–culture
conﬁrmed TB shortly after
29th September 08 Resistance to all ﬁrst main line
drugs reported. Patient was
admitted to Infectious Diseases
Unit in a negative pressure
room and TB treatment
stopped.
20th October 08 Resistance to streptomycin,
kanamycin, moxoﬂoxacin,
oﬂoxacin and p-aminosalicylic
acid reported. Re-started
treatment with clarithromycin,
cycloserine, linezolid,
protionamide, amikacin and
clofozimine
3rd March 09 Discharge from hospital
April 10 Treatment stopped
February 11 Last reviewed (followed up
every 6 months)
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DiscussionCase investigation and management
Thames Valley Health Protection Unit (TVHPU) was
notiﬁed of a case of TB in August 2008. A 22-
year-old student, HIV negative from Lithuania was
initially treated for pneumonia but later found
to have XDR-TB, the ﬁrst case in Thames Val-
ley and South East Region. The 24-locus Variable
Number Tandem Repeat (VNTR) proﬁle for a cul-
ture of Mycobacterium tuberculosis obtained from
the patient matched with 14 other individuals
in the UK, 5 of which were from Lithuania. No
social or epidemiological ink was established with
the other cases. After ﬁve months of hospital-
ization, the patient was discharged to continue
treatment at home, completing 16 months of the
planned two years of treatment due to intolera-
ble side effects. The patient has had six monthly
followup appointments and has had no progres-
sion of disease. The clinical details of the case
X
wM. Abid et al.
ere published as a case report in the British Med-
cal Journal [4] and are outlined in the timeline
Table 1).
ublic health interventions (s)
ommunication
TB incident control team was arranged shortly
fter the diagnosis of XDR-TB, to discuss con-
act tracing and screening. Guidance was sought
rom the National MDR-TB Clinical Advice Ser-
ice [5], which helps clinicians implement the
ost effective treatment. The public health
uthorities provide a useful communications link
y ensuring clinicians are aware of this ser-
ice from the moment a case of MDR-TB is
otiﬁed.
Other Health Protection Units nearby were con-
acted to identify potential links with other cases.
ontact tracing and screening
he TB nurse arranged contact tracing follow-
ng initial TB diagnosis. Five close contacts were
creened using Mantoux testing, Interferon gamma
ssay and a chest radiograph. Only one positive
ontact was identiﬁed who was asymptomatic. UK
ational guidelines on tuberculosis [6] were fol-
owed tomanage this contact; no chemoprophylaxis
as given, yearly follow up was arranged and
dvice was given to contact TB services immedi-
tely if any symptoms suggestive of TB develop.
his contact has remained asymptomatic and is in
ontact with the TB nurse. Public health advice
as also given to the patient’s place of work
nd study in order to identify other potential
ontacts.
A relative who had stayed with the patient in the
K while the patient had been symptomatic and had
ince returned to Lithuania was later identiﬁed as
n additional contact. Direct contact with the rela-
ive was not possible, but the patient was asked to
dvise the relative to be screened locally. The rel-
tive was a medical student and the public health
uthorities in Lithuania were informed. This con-
act had no respiratory symptoms and there were
o abnormal changes on the chest X-ray.DR-TB exists in Europe and 149 cases of XDR-TB
ere reported during 2003—2007, the majority of
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[case of XDR-TB in the UK
hich were from East European countries (58 were
stonia; 53 from Latvia and 25 from Lithuania) [7].
n the UK 10 cases of XDR-TB were reported in
he period of 1995—2008 [3]. Increasing migration
ithin the European Union and worldwide will cer-
ainly see these numbers rise in low risk countries
uch as UK.
The Eastern European background of this patient
eﬂects epidemiological trends in drug-resistant TB
nd could have alerted clinicians earlier to the
ossibility of XDR-TB. Current NICE guidelines [6],
owever, do not speciﬁcally highlight the risk of
rug-resistant TB in patients from countries, such as
ithuania, where there is a relatively low incidence
f TB overall, but a high proportion of MDR/XDR-TB
ases. Future UK cases of XDR-TB may have similar
emographic proﬁles and guidelines inmanagement
ould be reviewed to include this epidemiological
nowledge.
This case illustrates some of the difﬁculties
ncountered when tracing contacts living out-
ide the UK, raising the question of how far
o go when investigating the source of infec-
ion. There is a need for agreements between
ther national authorities to overcome these prob-
ems.
Successful management of XDR-TB relies upon
rompt diagnosis, notiﬁcation and treatment of
ases, a problem with TB generally. This patient
emained symptomatic for three months before
ffective treatment was started, allowing pro-
onged exposure to contacts and increasing the
isk of a potential outbreak. Concerns were raised
egarding the delay in diagnosis of this case and
he speed of the laboratory diagnostic tests. The
putum culture on this case did not grow very
ell which delayed the drug susceptibility test-
ng (DST) for the ﬁrst and second line drugs. DST
s done as a twostage process initially for ﬁrst-
ine drugs and then for secondline drugs. Testing
wider panel early when drug resistance is sus-
ected would increase the speed of reporting. The
nfectious Diseases Unit involved in this case now
ast-tracks all smear positive sputum samples to
he reference laboratory for rapid drug sensitivity
esting.
After diagnosis, strict monitoring of treat-
ent is essential to ensure successful outcomes.
he patient started directly observed therapy
DOT) in hospital, but was trained to self-
dminister medication prior to discharge, making
t difﬁcult to ensure 100% adherence. National
uidelines recommend DOT for treating MDR and
DR-TB cases but its enforcement can be difﬁ-
ult.
[
[209
At present, cases of XDR-TB are expected to be
poradic, however, a single outbreak could lead
o XDR-TB being established within the UK pop-
lation or sub-population. The resources needed
o manage this case were substantial, including
osts of clinical care, expensive anti-TB medica-
ions, work load of contact tracing and follow
p.
onclusion
DR-TB has a high mortality rate and is a signif-
cant public health threat. Highlighting patients
rom countries with a high proportion of MDR-
B and expediting drug susceptibility testing in
hese patients would aid more rapid diagnosis.
fﬁcient contact tracing, resource management
nd strict adherence to medication, will all be
ssential in the successful prevention of future
ases.
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